» Articles » PMID: 15520174

Overexpression of Histone Deacetylase 1 Confers Resistance to Sodium Butyrate-mediated Apoptosis in Melanoma Cells Through a P53-mediated Pathway

Overview
Journal Cancer Res
Specialty Oncology
Date 2004 Nov 3
PMID 15520174
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Melanoma cells typically express wild-type p53, yet they are notoriously resistant to DNA-damaging agents. Here, we show that sodium butyrate (NaB), a histone deacetylase (HDAC) inhibitor, induced apoptosis in human melanoma cells in a dose- and time-dependent manner. Apoptosis was associated with HDAC1-dependent induction of Bax and acetylation of p53. Down-regulation of HDAC1 by an antisense vector sensitized the cells to NaB-induced apoptosis, whereas its overexpression conferred resistance to this agent. Increased HDAC1 levels and activity impaired NaB-mediated activation of Bax promoter and Bax protein levels. Finally, using p53-null melanoma cell line and RNA interference in cells expressing wild-type p53 protein, we show that Bax induction and NaB-mediated apoptosis is p53 dependent.

Citing Articles

Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations.

Hao B, Ma K, Xu J, Fan R, Zhao W, Jia X Acta Pharmacol Sin. 2024; 45(6):1305-1315.

PMID: 38383757 PMC: 11130134. DOI: 10.1038/s41401-024-01236-5.


Association of changes in expression of and genes after drug treatment with cancer cell line sensitivity to kinase inhibitors.

Krushkal J, Zhao Y, Roney K, Zhu W, Brooks A, Wilsker D Epigenetics. 2024; 19(1):2309824.

PMID: 38369747 PMC: 10878021. DOI: 10.1080/15592294.2024.2309824.


Discovery of New Uracil and Thiouracil Derivatives as Potential HDAC Inhibitors.

Elbatrawy O, Hagras M, El Deeb M, Agili F, Hegazy M, El-Husseiny A Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513878 PMC: 10384246. DOI: 10.3390/ph16070966.


The role of protein acetylation in carcinogenesis and targeted drug discovery.

Yang J, Song C, Zhan X Front Endocrinol (Lausanne). 2022; 13:972312.

PMID: 36171897 PMC: 9510633. DOI: 10.3389/fendo.2022.972312.


Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy.

Islam S, Espitia C, Persky D, Carew J, Nawrocki S Blood Adv. 2020; 4(20):5297-5310.

PMID: 33108458 PMC: 7594386. DOI: 10.1182/bloodadvances.2020002297.